non-nucleoside reverse transcription

Lersivirine (UK-453061)(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.

Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) that inhibits HIV replication by inhibiting HIV-1 reverse transcriptase activity and preventing the transcription of viral RNA into DNA for use in Highly Active Antiretroviral Therapy (HAART) programs and HIV disease studies

HEPT is a non-nucleoside inhibitor of HIV-1 reverse transcription.

Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. It works by non-competitively binding to HIV-1 reverse transcriptase and altering its conformation, thereby inhibiting the reverse transcription of viral RNA into DNA. In vitro, its half-maximal inhibitory concentration (IC₅₀) against HIV-1 reverse transcriptase can be as low as the nanomolar range (0.26 μM).